| Bausch Health US, LLC |
00187000625 |
CABTREO™ (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel, 1.2%/0.15%/3.1%, 50g Pump |
Brand |
FDA |
2023-12-11 |
950.0000 |
None |
1 |
50000000 |
None |
None |
None |
None |
None |
None |
Comment regarding patient estimate: There are an estimated 50 million patients that suffer from acne vulgaris. We do not know how many patients will be prescribed CABTREO™; Comment regarding acquisition: CABTREO™ was developed internally, not acquired. |
None |
| Baxter Healthcare Corporation |
10019007901 |
Bendamustine HCl Injection |
Brand |
FDA |
2023-02-08 |
2340.0000 |
None |
1 |
1000 |
None |
None |
None |
None |
None |
None |
Estimated number of patients is based on per year. |
None |
| Baxter Healthcare Corporation |
43066008910 |
Foscarnet Sodium Injection |
Generic |
FDA |
2023-09-22 |
3600.0000 |
Not required for generic drugs. |
None |
700 |
1 |
None |
None |
None |
None |
None |
None |
None |
| Bayer |
50419039302 |
VITRAKVI 20MG/ML SOLU BT 1X50ML |
Brand |
FDA |
2023-04-19 |
8250.5000 |
Product is not new. Oral Solution has changed from 1x100ml bottle to 2x50ml bottles. Everything remains consistent with previous marketing plan. |
None |
60 |
None |
None |
None |
None |
None |
None |
Price setting is a part of the company?s overall global competitive strategy and is developed by the company?s senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace |
https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=679 |
| Bayer |
50419039303 |
VITRAKVI 20MG/ML SOLU BT 2X50ML US |
Brand |
FDA |
2023-04-19 |
16501.0000 |
Product is not new. Oral Solution has changed from 1x100ml bottle to 2x50ml bottles. Everything remains consistent with previous marketing plan. |
None |
60 |
None |
None |
None |
None |
None |
None |
Price setting is a part of the company?s overall global competitive strategy and is developed by the company?s senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace |
https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=680 |
| BE Pharmaceuticals Inc. |
71839013710 |
Carboprost Tromethamine Intramuscular Solution, 250 MCG/mL, 1mL vials, 10 count in 1 box. |
Generic |
FDA |
2023-06-09 |
1330.0000 |
None |
1 |
14000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Biocon Biologics Inc. |
83257000541 |
FULPHILA® (pegfilgrastim-jmdb) injection 6 mg/0.6 mL -Single-Dose Prefilled Syringe |
Generic |
FDA |
2023-10-03 |
2087.5000 |
This is a new NDC for a product acquired by Biocon in November 2022. There are no additional changes to the marketing approach for this NDC change. Possible marketing activities include general advertisements, direct-to-consumer promotional incentives, and promotion of the drug to physicians or other health professionals based on the approved indication of the product as detailed in the product's FDA approved label. |
None |
22000 |
None |
None |
2022-11-29 |
None |
1 |
Biocon acquired the biosimiliar product portfolio of Viatris in November 2022. Biocon is now launching a new NDC for this particular acquired product. |
None |
None |
| Biocon Biologics Inc. |
83257000412 |
Ogivri (trastuzumab-dkst) for injection 420 mg/Vial, Multi-Dose Vial and Bacteriostatic Water for Injection, USP, Multiple-Dose vial -20 mL |
Brand |
FDA |
2023-10-03 |
2625.0500 |
This is a new NDC for a product acquired by Biocon in November 2022. There are no additional changes to the marketing approach for this NDC change. Possible marketing activities include general advertisements, direct-to-consumer promotional incentives, and promotion of the drug to physicians or other health professionals based on the approved indication of the product as detailed in the product's FDA approved label. |
None |
40151 |
None |
None |
2022-11-29 |
None |
1 |
Biocon acquired the biosimiliar product portfolio of Viatris in November 2022. Biocon is now launching a new NDC for this particular acquired product. |
None |
None |
| Biocon Biologics Inc. |
83257000111 |
Ogivri (trastuzumab-dkst) for injection 150 mg/Vial, Single-Dose Vial |
Brand |
FDA |
2023-10-04 |
940.5100 |
This is a new NDC for a product acquired by Biocon in November 2022. There are no additional changes to the marketing approach for this NDC change. Possible marketing activities include general advertisements, direct-to-consumer promotional incentives, and promotion of the drug to physicians or other health professionals based on the approved indication of the product as detailed in the product's FDA approved label. |
None |
40151 |
None |
None |
2022-11-29 |
None |
1 |
Biocon acquired the biosimiliar product portfolio of Viatris in November 2022. Biocon is now launching a new NDC for this particular acquired product. |
None |
None |
| Biocon Limited |
70377001311 |
Everolimus Tablets 10mg 30ct |
Generic |
FDA |
2023-07-11 |
1600.0000 |
Change of packing configuration from 28ct blister to 30ct bottle. Supplied to large wholesalers and specialty pharmacies including AmerisourceBergen, Oncology Supply, Cardinal Health, McKesson, CVS Health Specialty, and Acaria. Biocon offers an eVoucherRx® program to lower patient co-pays at the point of sale. |
None |
11000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Biocon Limited |
70377001211 |
Everolimus Tablets 7.5mg 30ct |
Generic |
FDA |
2023-09-20 |
1600.0000 |
Change of packing configuration from 28ct blister to 30ct bottle. Supplied to large wholesalers and specialty pharmacies including AmerisourceBergen, Oncology Supply, Cardinal Health, McKesson, CVS Health Specialty, and Acaria. Biocon offers an eVoucherRx® program to lower patient co-pays at the point of sale. |
None |
2300 |
None |
None |
None |
None |
None |
None |
None |
None |
| Biocon Limited |
70377001111 |
Everolimus Tablets 5mg 30ct |
Generic |
FDA |
2023-11-09 |
1600.0000 |
Change of packing configuration from 28ct blister to 30ct bottle. Supplied to large wholesalers and specialty pharmacies including AmerisourceBergen, Oncology Supply, Cardinal Health, McKesson, CVS Health Specialty, and Acaria. Biocon offers an eVoucherRx® program to lower patient co-pays at the point of sale. There were not amounts spent on direct-to-consumer marketing or advertising, as well as not amount spent to promote the drugs to physicians. |
None |
6500 |
None |
None |
None |
None |
None |
None |
None |
None |
| Biogen |
64406010901 |
Qalsody 100 mg/15 mL (6.7 mg/mL) solution in a single-dose vial |
Brand |
FDA |
2023-04-25 |
14230.0000 |
QALSODY will be marketed to Healthcare Professionals, Patients, Payers, and other appropriate audiences.
Biogen has a set of Pricing Principles that inform pricing decisions for its products. Those principles are: 1. Value to Patients, 2. Present and Future Benefit to Society, 3. Fulfilling our commitment to Innovation, 4. Evolution toward Value Based Care, and 5. Affordability & Sustainability.
Further information can be found at:
https://www.biogen.com/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf |
None |
330 |
None |
1 |
None |
None |
None |
None |
QALSODY ™ (tofersen) is a 100 mg/15 mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. The estimated number of patients provided in column #7 is the number of people in the U.S. living with the disease. |
None |
| Biogen |
64406002901 |
ZURZUVAE 20mg capsules in a 14-count bottle |
Brand |
FDA |
2023-12-01 |
7950.0000 |
ZURZUVAE will be marketed to Healthcare Professionals, Patients, Payers, and other appropriate audiences.
Biogen has a set of Pricing Principles that inform pricing decisions for its products. Those principles are: 1. Value to Patients, 2. Present and Future Benefit to Society, 3. Fulfilling our commitment to Innovation, 4. Evolution toward Value Based Care, and 5. Affordability & Sustainability.
Further information can be found at:
https://www.biogen.com/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf |
None |
500000 |
1 |
1 |
None |
None |
None |
None |
The estimated number of patients provided is the number of women in the United States who report experiencing symptoms of postpartum depression each year. |
None |
| Biogen |
64406003002 |
ZURZUVAE 25mg capsules in a 28-count blister pack |
Brand |
FDA |
2023-12-01 |
15900.0000 |
ZURZUVAE will be marketed to Healthcare Professionals, Patients, Payers, and other appropriate audiences.
Biogen has a set of Pricing Principles that inform pricing decisions for its products. Those principles are: 1. Value to Patients, 2. Present and Future Benefit to Society, 3. Fulfilling our commitment to Innovation, 4. Evolution toward Value Based Care, and 5. Affordability & Sustainability.
Further information can be found at:
https://www.biogen.com/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf |
None |
500000 |
1 |
1 |
None |
None |
None |
None |
The estimated number of patients provided is the number of women in the United States who report experiencing symptoms of postpartum depression each year. |
None |
| Biogen |
64406003101 |
ZURZUVAE 30mg capsules in a 14-count bottle |
Brand |
FDA |
2023-12-01 |
15900.0000 |
ZURZUVAE will be marketed to Healthcare Professionals, Patients, Payers, and other appropriate audiences.
Biogen has a set of Pricing Principles that inform pricing decisions for its products. Those principles are: 1. Value to Patients, 2. Present and Future Benefit to Society, 3. Fulfilling our commitment to Innovation, 4. Evolution toward Value Based Care, and 5. Affordability & Sustainability.
Further information can be found at:
https://www.biogen.com/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf |
None |
500000 |
1 |
1 |
None |
None |
None |
None |
The estimated number of patients provided is the number of women in the United States who report experiencing symptoms of postpartum depression each year. |
None |
| BiolineRX LTD |
82737007301 |
APHEXDA (motixafortide) For Injection: 62 mg as a lyophilized powder in a single-dose vial for reconstitution.The recommended dosage of APHEXDA is 1.25 mg/kg administered via subcutaneous injection. |
Brand |
FDA |
2023-09-22 |
5900.0000 |
APHEXDA will be promoted by our Transplant Account Managers to healthcare professionals to educate them on our product via in-office and virtual visits. Pricing was established by a comprehensive review of the competitive market and market conditions, years of product development investments, and various operational costs. |
None |
8000 |
None |
None |
None |
None |
None |
None |
None |
None |
| BioMarin Pharmaceutical Inc |
68135092748 |
ROCTAVIAN (valoctocogene roxaparvovec-rvox) suspension for intravenous infusion is supplied in vials designed to deliver 8 mL. Each mL contains 2 × 10^13 vector genomes. The recommended dose of ROCTAVIAN is 16 × 10^13 vector genomes per kg of body weight. |
Brand |
FDA |
2023-08-16 |
90625.0000 |
Consistent with Cal Health & Safety Code 127681(c), BioMarin’s response is limited to information publicly available/in public domain. The marketing and pricing plans are confidential and proprietary and are not in the public domain or publicly available. |
None |
27 |
1 |
None |
None |
None |
None |
None |
None |
None |
| Boehringer Ingelheim |
00597044587 |
PRADAXA® 110mg Oral Pellets |
Brand |
FDA |
2023-02-14 |
4717.4600 |
Specific Marketing and Pricing Plans for Pradaxa Pellets® are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price. These factors included: the value of innovative medicines; investments made (including in research and development), manufacturing, and other costs and the risks undertaken. Boehringer Ingelheim invests 20% of its net sales into research and development. |
None |
3500 |
None |
1 |
None |
None |
None |
None |
The WAC at Intro to Market is $4717.46 (not $4717.16) and we have been unable to make the correction in Column 4 in the online system for this NDC. Pursuant to SB17, the information reported is limited to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597045016 |
PRADAXA® 150mg Oral Pellets |
Brand |
FDA |
2023-02-14 |
4717.4600 |
Specific Marketing and Pricing Plans for Pradaxa Pellets® are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price. These factors included: the value of innovative medicines; investments made (including in research and development), manufacturing, and other costs and the risks undertaken. Boehringer Ingelheim invests 20% of its net sales into research and development. |
None |
3500 |
None |
1 |
None |
None |
None |
None |
The WAC at Intro to Market is $4717.46 (not $4717.16) and we have been unable to make the correction in Column 4 in the online system for this NDC. Pursuant to SB17, the information reported is limited to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597042578 |
PRADAXA® 20mg Oral Pellets |
Brand |
FDA |
2023-02-14 |
4717.4600 |
Specific Marketing and Pricing Plans for Pradaxa Pellets® are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price. These factors included: the value of innovative medicines; investments made (including in research and development), manufacturing, and other costs and the risks undertaken. Boehringer Ingelheim invests 20% of its net sales into research and development. |
None |
3500 |
None |
1 |
None |
None |
None |
None |
Pursuant to SB17, the information reported is limited to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597043018 |
PRADAXA® 30mg Oral Pellets |
Brand |
FDA |
2023-02-14 |
4717.4600 |
Specific Marketing and Pricing Plans for Pradaxa Pellets® are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price. These factors included: the value of innovative medicines; investments made (including in research and development), manufacturing, and other costs and the risks undertaken. Boehringer Ingelheim invests 20% of its net sales into research and development. |
None |
3500 |
None |
1 |
None |
None |
None |
None |
Pursuant to SB17, the information reported is limited to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597043596 |
PRADAXA® 40mg Oral Pellets |
Brand |
FDA |
2023-02-14 |
4717.4600 |
Specific Marketing and Pricing Plans for Pradaxa Pellets® are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price. These factors included: the value of innovative medicines; investments made (including in research and development), manufacturing, and other costs and the risks undertaken. Boehringer Ingelheim invests 20% of its net sales into research and development. |
None |
3500 |
None |
1 |
None |
None |
None |
None |
Pursuant to SB17, the information reported is limited to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597044053 |
PRADAXA® 50mg Oral Pellets |
Brand |
FDA |
2023-02-14 |
4717.4600 |
Specific Marketing and Pricing Plans for Pradaxa Pellets® are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price. These factors included: the value of innovative medicines; investments made (including in research and development), manufacturing, and other costs and the risks undertaken. Boehringer Ingelheim invests 20% of its net sales into research and development. |
None |
3500 |
None |
1 |
None |
None |
None |
None |
Pursuant to SB17, the information reported is limited to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597037597 |
Cyltezo Pen 40mg/0.8mL (50mg/mL) 2ct |
Brand |
FDA |
2023-07-01 |
6576.4900 |
Specific Marketing and Pricing Plans for Cyltezo are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 21% of its net sales into research and development, including clinical trials. |
None |
20000000 |
None |
None |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597037523 |
Cyltezo Pen 40mg/0.8mL (50mg/mL) 4ct |
Brand |
FDA |
2023-07-01 |
13152.9800 |
Specific Marketing and Pricing Plans for Cyltezo are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 21% of its net sales into research and development, including clinical trials. |
None |
20000000 |
None |
None |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597037516 |
Cyltezo Pen 40mg/0.8mL (50mg/mL) 6ct |
Brand |
FDA |
2023-07-01 |
19729.4700 |
Specific Marketing and Pricing Plans for Cyltezo are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 21% of its net sales into research and development, including clinical trials. |
None |
20000000 |
None |
None |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597040089 |
Cyltezo PFS 10mg/0.2mL (50mg/mL) 2ct |
Brand |
FDA |
2023-07-01 |
6576.4900 |
Specific Marketing and Pricing Plans for Cyltezo are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 21% of its net sales into research and development, including clinical trials. |
None |
20000000 |
None |
None |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597040580 |
Cyltezo PFS 20mg/0.4mL (50mg/mL) 2ct |
Brand |
FDA |
2023-07-01 |
6576.4900 |
Specific Marketing and Pricing Plans for Cyltezo are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 21% of its net sales into research and development, including clinical trials. |
None |
20000000 |
None |
None |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597037082 |
Cyltezo PFS 40mg/0.8mL (50mg/mL) 2ct |
Brand |
FDA |
2023-07-01 |
6576.4900 |
Specific Marketing and Pricing Plans for Cyltezo are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 21% of its net sales into research and development, including clinical trials. |
None |
20000000 |
None |
None |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597054522 |
adalimumab-adbm Pen 40mg/0.8mL (50mg/mL) 2ct |
Brand |
FDA |
2023-10-02 |
1315.3000 |
Specific Marketing and Pricing Plans for adalimumab-adbm are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, consideration for access to patients and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 21% of its net sales into research and development, including clinical trials. |
None |
20000000 |
None |
None |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597054544 |
adalimumab-adbm Pen 40mg/0.8mL (50mg/mL) 4ct |
Brand |
FDA |
2023-10-02 |
2630.6000 |
Specific Marketing and Pricing Plans for adalimumab-adbm are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, consideration for access to patients and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 21% of its net sales into research and development, including clinical trials. |
None |
20000000 |
None |
None |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597054566 |
adalimumab-adbm Pen 40mg/0.8mL (50mg/mL) 6ct |
Brand |
FDA |
2023-10-02 |
3945.8900 |
Specific Marketing and Pricing Plans for adalimumab-adbm are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, consideration for access to patients and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 21% of its net sales into research and development, including clinical trials. |
None |
20000000 |
None |
None |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597058589 |
adalimumab-adbm PFS 10mg/0.2mL (50mg/mL) 2ct |
Brand |
FDA |
2023-10-02 |
1315.3000 |
Specific Marketing and Pricing Plans for adalimumab-adbm are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, consideration for access to patients and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 21% of its net sales into research and development, including clinical trials. |
None |
20000000 |
None |
None |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597055580 |
adalimumab-adbm PFS 20mg/0.4mL (50mg/mL) 2ct |
Brand |
FDA |
2023-10-02 |
1315.3000 |
Specific Marketing and Pricing Plans for adalimumab-adbm are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, consideration for access to patients and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 21% of its net sales into research and development, including clinical trials. |
None |
20000000 |
None |
None |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. |
None |
| Boehringer Ingelheim |
00597059520 |
adalimumab-adbm PFS 40mg/0.8mL (50mg/mL) 2ct |
Brand |
FDA |
2023-10-02 |
1315.3000 |
Specific Marketing and Pricing Plans for adalimumab-adbm are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, consideration for access to patients and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 21% of its net sales into research and development, including clinical trials. |
None |
20000000 |
None |
None |
None |
None |
None |
None |
Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. |
None |
| Braeburn Rx |
58284022801 |
BRIXADI 128 mg/0.36 mL; injection, solution |
Brand |
FDA |
2023-08-15 |
1595.0000 |
None |
1 |
3000000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Braeburn Rx |
58284021601 |
BRIXADI 16 mg/0.32 mL; injection, solution |
Brand |
FDA |
2023-08-15 |
415.0000 |
None |
1 |
3000000 |
None |
None |
None |
None |
None |
None |
This is a weekly product. The total cost for a four week supply is $1,660.00. |
None |
| Braeburn Rx |
58284022401 |
BRIXADI 24 mg/0.48 mL; injection, solution |
Brand |
FDA |
2023-08-15 |
415.0000 |
None |
1 |
3000000 |
None |
None |
None |
None |
None |
None |
This is a weekly product. The total cost for a four week supply is $1,660.00. |
None |
| Braeburn Rx |
58284023201 |
BRIXADI 32 mg/0.64 mL; injection, solution |
Brand |
FDA |
2023-08-15 |
415.0000 |
None |
1 |
3000000 |
None |
None |
None |
None |
None |
None |
This is a weekly product. The total cost for a four week supply is $1,660.00. |
None |
| Braeburn Rx |
58284026401 |
BRIXADI 64 mg/0.18 mL; injection, solution |
Brand |
FDA |
2023-08-15 |
1595.0000 |
None |
1 |
3000000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Braeburn Rx |
58284020801 |
BRIXADI 8 mg/0.16 mL; injection, solution |
Brand |
FDA |
2023-08-15 |
415.0000 |
None |
1 |
3000000 |
None |
None |
None |
None |
None |
None |
This is a weekly product. The total cost for a four week supply is $1,660.00. |
None |
| Braeburn Rx |
58284029601 |
BRIXADI 96 mg/0.27 mL; injection, solution |
Brand |
FDA |
2023-08-15 |
1595.0000 |
None |
1 |
3000000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Bristol Myers Squibb |
00003404012 |
AUGTYRO™ (repotrectinib) 40mg capsules are available in bottles of 120 count for oral use. AUGTYRO™ hard shell capsules are white, opaque, immediate release, Size 0, filled with white to off-white powder which may appear as a plug, imprinted with “REP 40” |
Brand |
FDA |
2023-11-16 |
14500.0000 |
We consider multiple factors when setting a list price for a medicine, including: (i) The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. (ii) Market and business considerations, including: Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; and Medical- and patient-service costs; this includes funding growing patient assistance programs; Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
35 |
1 |
1 |
2022-08-17 |
4100000000.0000 |
None |
Bristol Myers Squibb acquired Turning Point Therapeutics for $76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and closed during the third quarter of 2022. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis. |
Comment regarding "Estimated Number of Patients": 30-35 patients per month (forecast). This number reflects estimate for average new patients starts only and does not include continuing patients from previous months. Estimate reflects new patients across all channels (commercial and access programs for 2024). However, BMS is unable to provide an exact number of patients who will be prescribed AUGTYRO each month. |
None |
| Bristol Myers Squibb |
00003404060 |
AUGTYRO™ (repotrectinib) 40mg capsules are available in bottles of 60 count for oral use. AUGTYRO™ hard shell capsules are white, opaque, immediate release, Size 0, filled with white to off-white powder which may appear as a plug, imprinted with “REP 40” |
Brand |
FDA |
2023-11-16 |
7250.0000 |
We consider multiple factors when setting a list price for a medicine, including: (i) The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. (ii) Market and business considerations, including; Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; and Medical- and patient-service costs; this includes funding growing patient assistance programs; Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
35 |
1 |
1 |
2022-08-17 |
4100000000.0000 |
None |
Bristol Myers Squibb acquired Turning Point Therapeutics for $76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and closed during the third quarter of 2022. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis. |
Comment regarding "Estimated Number of Patients": 30-35 patients per month (forecast). This number reflects estimate for average new patients starts only and does not include continuing patients from previous months. Estimate reflects new patients across all channels (commercial and access programs for 2024). However, BMS is unable to provide an exact number of patients who will be prescribed AUGTYRO each month. |
None |